1-4 of 4
Eugenia Kraynov
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody

Amir A. Al-Khami, Sawsan Youssef, Yasmina Abdiche, HoangKim Nguyen, Joyce Chou, Christopher R. Kimberlin, Sherman M. Chin, Cris Kamperschroer, Bart Jessen, Brent Kern, Natalija Budimir, Christopher P. Dillon, Allison Xu, Jerry D. Clark, Jeffrey Chou, Eugenia Kraynov, Arvind Rajpal, John C. Lin, Shahram Salek-Ardakani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (10): 2105–2116.
https://doi.org/10.1158/1535-7163.MCT-20-0093
Published: 02 October 2020
View articletitled, Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
Open the PDF for Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody in another window
Includes: Supplementary data
Journal Articles

RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

Pavel Strop, Thomas-Toan Tran, Magdalena Dorywalska, Kathy Delaria, Russell Dushin, Oi Kwan Wong, Wei-Hsien Ho, Dahui Zhou, Aidong Wu, Eugenia Kraynov, Laura Aschenbrenner, Bora Han, Christopher J. O'Donnell, Jaume Pons, Arvind Rajpal, Dave L. Shelton, Shu-Hui Liu
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (11): 2698–2708.
https://doi.org/10.1158/1535-7163.MCT-16-0431
Published: 01 November 2016
View articletitled, RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
Open the PDF for RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models in another window
Includes: Supplementary data
Journal Articles

Abstract PR-2: Discovery of p21‐activated kinase inhibitor PF‐03758309

Chuangxing Guo, Junhu Zhang, Indrawan McAlpine, Catherine Johnson, Joseph Marakovits, Liming Dong, Susan Kephart, Anle Yang, Jayashree Tikhe, Haitao Li, Lisa Guo, Djamal Bouzida, Ya‐Li Deng, Dan Knighton, Joseph Piraino, Joseph Lee, Tod Smeal, Jamie Christensen, Eugenia Kraynov, Cho‐Ming Loi, Hasam Younis, Eleanor Dagostino, Brion W. Murray
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): PR-2.
https://doi.org/10.1158/1535-7163.TARG-09-PR-2
Published: 10 December 2009
View articletitled, Abstract PR-2: Discovery of p21‐activated kinase inhibitor PF‐03758309
Journal Articles

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

Alessandra Blasina, Jill Hallin, Enhong Chen, Maria Elena Arango, Eugenia Kraynov, James Register, Stephan Grant, Sacha Ninkovic, Ping Chen, Tim Nichols, Patrick O'Connor, Kenna Anderes
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (8): 2394–2404.
https://doi.org/10.1158/1535-7163.MCT-07-2391
Published: 21 August 2008
View articletitled, Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
Open the PDF for Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 in another window
Includes: Supplementary data